Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

Core Viewpoint - Inhibikase Therapeutics is advancing its lead product candidate IKT-001 towards a late-stage clinical trial for Pulmonary Arterial Hypertension (PAH), with expectations to initiate a Phase 2b study in the second half of 2025 [2][7]. Recent Developments - The company has finalized the study protocol for the Phase 2b clinical study, named IMPROVE-PAH, which will involve approximately 150 PAH participants [2][7]. - The study will randomize participants to receive either 300 mg or 500 mg of IKT-001 or a placebo once daily for 26 weeks, alongside stable background PAH therapy [7]. - Previous studies have shown that imatinib mesylate, the active component of IKT-001, has demonstrated significant efficacy in improving patient outcomes in PAH [2]. Financial Results - As of June 30, 2025, the company reported cash, cash equivalents, and marketable securities totaling $87.7 million, down from $97.5 million at the end of 2024 [4]. - The net loss for the quarter ended June 30, 2025, was $9.9 million, or $0.11 per share, compared to a net loss of $5.0 million, or $0.66 per share, in the same quarter of 2024 [5]. - Research and development expenses increased to $5.3 million for the quarter ended June 30, 2025, compared to $3.1 million for the same period in 2024 [6]. - Selling, general and administrative expenses rose to $5.9 million for the quarter ended June 30, 2025, compared to $2.0 million for the same quarter in 2024 [8].